東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

FindBook

Google Book

Amazon

博客來

Optimizing Treatment Outcomes of Dorsomedial Prefrontal Cortex Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Optimizing Treatment Outcomes of Dorsomedial Prefrontal Cortex Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder./
作者:	Schulze, Laura.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2021,
面頁冊數:	216 p.
附註:	Source: Dissertations Abstracts International, Volume: 83-01, Section: B.
Contained By:	Dissertations Abstracts International83-01B.
標題:	Neurosciences. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28317626
ISBN:	9798522943516

Optimizing Treatment Outcomes of Dorsomedial Prefrontal Cortex Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder.
Schulze, Laura.

Optimizing Treatment Outcomes of Dorsomedial Prefrontal Cortex Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder. - Ann Arbor : ProQuest Dissertations & Theses, 2021 - 216 p.

Source: Dissertations Abstracts International, Volume: 83-01, Section: B.

Thesis (Ph.D.)--University of Toronto (Canada), 2021.

This item must not be sold to any third party vendors.

Major depressive disorder (MDD) continues to challenge the field of psychiatry with its suboptimal treatment outcomes. In cases of partial or non-response to first-line treatments, alternative treatment options are available. Unfortunately, even with these pharmacological advances, there remains a proportion of patients who experience minimal relief from their depressive symptoms.Repetitive transcranial magnetic stimulation (rTMS) is an emerging form of brain stimulation used in the treatment of refractory psychiatric and neurological disorders. The most widely used target for rTMS in MDD is the dorsolateral prefrontal cortex (DLPFC); however, the treatment outcomes it yields are moderate. Over recent years, alternative stimulation targets have emerged as a potential solution to this issue; among them is the dorsomedial prefrontal cortex (DMPFC). To our knowledge, the DMPFC has not been systematically investigated like its adjacent prefrontal counterpart, the DLPFC. Therefore, the primary aim of the present thesis is to examine, and to further optimize treatment outcomes of DMPFC-rTMS in MDD.We addressed this research question using multiple cohorts of MDD patients receiving DMPFC-rTMS. First, we explored the safety and tolerability of DMPFC-rTMS, focusing primarily on its cognitive profile (Study I). Second, we compared treatment outcomes for DMPFC-rTMS between individuals undergoing concurrent antipsychotic pharmacotherapy versus those receiving rTMS alone (Study II). Finally, Experiments III and IV were untaken to investigate accelerated rTMS; that is, whether the pace of symptom improvement can be increased through the use of a more intensive protocol consisting of multiple daily rTMS sessions.Encouragingly, results from this body of work demonstrate that DMPFC-rTMS is a safe and well-tolerated, treatment for MDD (Study I), even in patients undergoing concurrent antipsychotic therapy (Study II). Congruent with existing literature on accelerated rTMS, we found that the rate of improvement can be rapidly increased in some patients, by administering multiple daily sessions of rTMS (Study III), regardless of the intersession interval (Study IV). Collectively, this thesis provides support for the notion that the safety and efficacy of rTMS in MDD applies not only to the standard target, the DLPFC, but also to the DMPFC, a target of stimulation that is entering use.

ISBN: 9798522943516Subjects--Topical Terms:

588700
Neurosciences.
Subjects--Index Terms:

Brain stimulation

Optimizing Treatment Outcomes of Dorsomedial Prefrontal Cortex Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder.
LDR:03675nmm a2200385 4500 001 2347422
005 20220801062155.5
008 241004s2021 ||||||||||||||||| ||eng d
020 $a 9798522943516
035 $a (MiAaPQ)AAI28317626
035 $a AAI28317626
040 $a MiAaPQ $c MiAaPQ
100 1 $a Schulze, Laura. $3 3686664
245 1 0 $a Optimizing Treatment Outcomes of Dorsomedial Prefrontal Cortex Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2021
300 $a 216 p.
500 $a Source: Dissertations Abstracts International, Volume: 83-01, Section: B.
500 $a Advisor: Downar, Jonathan.
502 $a Thesis (Ph.D.)--University of Toronto (Canada), 2021.
506 $a This item must not be sold to any third party vendors.
520 $a Major depressive disorder (MDD) continues to challenge the field of psychiatry with its suboptimal treatment outcomes. In cases of partial or non-response to first-line treatments, alternative treatment options are available. Unfortunately, even with these pharmacological advances, there remains a proportion of patients who experience minimal relief from their depressive symptoms.Repetitive transcranial magnetic stimulation (rTMS) is an emerging form of brain stimulation used in the treatment of refractory psychiatric and neurological disorders. The most widely used target for rTMS in MDD is the dorsolateral prefrontal cortex (DLPFC); however, the treatment outcomes it yields are moderate. Over recent years, alternative stimulation targets have emerged as a potential solution to this issue; among them is the dorsomedial prefrontal cortex (DMPFC). To our knowledge, the DMPFC has not been systematically investigated like its adjacent prefrontal counterpart, the DLPFC. Therefore, the primary aim of the present thesis is to examine, and to further optimize treatment outcomes of DMPFC-rTMS in MDD.We addressed this research question using multiple cohorts of MDD patients receiving DMPFC-rTMS. First, we explored the safety and tolerability of DMPFC-rTMS, focusing primarily on its cognitive profile (Study I). Second, we compared treatment outcomes for DMPFC-rTMS between individuals undergoing concurrent antipsychotic pharmacotherapy versus those receiving rTMS alone (Study II). Finally, Experiments III and IV were untaken to investigate accelerated rTMS; that is, whether the pace of symptom improvement can be increased through the use of a more intensive protocol consisting of multiple daily rTMS sessions.Encouragingly, results from this body of work demonstrate that DMPFC-rTMS is a safe and well-tolerated, treatment for MDD (Study I), even in patients undergoing concurrent antipsychotic therapy (Study II). Congruent with existing literature on accelerated rTMS, we found that the rate of improvement can be rapidly increased in some patients, by administering multiple daily sessions of rTMS (Study III), regardless of the intersession interval (Study IV). Collectively, this thesis provides support for the notion that the safety and efficacy of rTMS in MDD applies not only to the standard target, the DLPFC, but also to the DMPFC, a target of stimulation that is entering use.
590 $a School code: 0779.
650 4 $a Neurosciences. $3 588700
650 4 $a Biomedical engineering. $3 535387
650 4 $a Experimental psychology. $3 2144733
650 4 $a Mental health. $3 534751
650 4 $a Health care management. $3 2122906
650 4 $a Antidepressants. $3 922074
650 4 $a Transcranial magnetic stimulation. $3 3686665
650 4 $a Parkinsons disease. $3 3562685
650 4 $a Mental disorders. $3 728624
650 4 $a Psychotropic drugs. $3 564250
650 4 $a Bipolar disorder. $3 3667114
650 4 $a Anxieties. $3 3544556
650 4 $a Kinases. $3 3558077
650 4 $a Post traumatic stress disorder. $3 3543866
650 4 $a Drug therapy. $3 3559056
653 $a Brain stimulation
653 $a DMPFC
653 $a Major depressive disorder
653 $a Repetitive Transcranial Magnetic Stimulation
690 $a 0317
690 $a 0541
690 $a 0347
690 $a 0623
690 $a 0769
710 2 $a University of Toronto (Canada). $b Medical Science. $3 3182952
773 0 $t Dissertations Abstracts International $g 83-01B.
790 $a 0779
791 $a Ph.D.
792 $a 2021
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28317626